- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Featured Search - 18F-FDG PET Predicts Outcome in Pediatric Brain Stem Glioma
Examination of baseline scans from a glioma-treatment trial of the Pediatric Brain Tumor Consortium shows that the pattern and intensity of uptake in 18F FDG uptake in children diagnosed with brainstem glioma correlated with overall and progression-free survival rates.
Top news from a Jan. 27 featured radiology search on SearchMedica: nuclear
Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain Stem Glioma: A Report from the Pediatric Brain Tumor ConsortiumThe Journal of Nuclear Medicine | Feb 1, 2011 (Free abstract. Full text $15)
Examination of baseline scans from a glioma-treatment trial of the Pediatric Brain Tumor Consortium shows that the pattern and intensity of uptake in 18F FDG PET scans in children diagnosed with brainstem glioma correlated with overall and progression-free survival rates.
Related content from Diagnostic Imaging:
FDG-PET/CT identifies aortic dissection
PET/CT imaging with FDG can identify when a tear in the wall of the aorta causes blood to flow between the wall's layers and forces the layers apart.
FDG-PET/CT provides added value in routine multiple imaging scans
In patients with suspected infection and no known history of cancer FDG-PET/CT can be a useful tool for localizing the infectious disease.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
